OXALIPLATIN (ELOXATIN) WITH BORTEZOMIB IN PATIENTS WITH ADVANCED MALIGNANCY

奥沙利铂（ELOXATIN）联合硼替佐米治疗晚期恶性肿瘤患者

• 批准号: 7605716
• 负责人: HOWARD S HOCHSTER
• 金额: $ 0.99万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605716
• 关键词: Advanced Malignant Neoplasm; Bortezomib; Cell Cycle Proteins; Computer Retrieval of Information on Scientific Projects Database; Cytoskeleton; Data; Dose; Dose-Limiting; Eloxatin; End Point; Enrollment; Exposure to; Funding; Goals; Grant; Infusion procedures; Institution; Malignant Neoplasms; Organ; Outpatients; PS341 cpd; Patients; Phase; Phase I Clinical Trials; Phase II Clinical Trials; Research; Research Personnel; Resources; Source; TP53 gene; Thalidomide; Toxic effect; Ubiquitin; United States National Institutes of Health; Visit; inhibitor/antagonist; multicatalytic endopeptidase complex; oxaliplatin

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a phase I trial of the combination of oxaliplatin and PS-341 (an inhibitor of ubiquitin-proteasome degradation of p53, IkB, and other cell-cycle regulatory proteins) in the treatment of advanced cancer. The goal is to determine the minimal dose requirements for phase II trials and to determine the toxicities of this combination of agents. Patients will be treated as outpatients and will receive infusions of accelerating doses of PS-341 prior to an infusion of oxaliplatin. Endpoints are the identification of a recommended phase II dose of PS-341 and determination of dose-limiting toxicity. 15-30 patients with advanced cancer, good organ function and lack of prior exposure to certain types of agents (thalidomide, cytoskeleton-active agents) will be enrolled, and participation will involve 26 visits for infusions over 3-6 months. The investigators continue to enroll subjects on this study. No data are available as of yet.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这是奥沙利铂和PS-341（一种p53、IkB和其他细胞周期调节蛋白的泛素-蛋白酶体降解抑制剂）联合治疗晚期癌症的I期试验。 目的是确定II期试验的最小剂量要求，并确定这种药物组合的毒性。 患者将作为门诊患者接受治疗，并在输注奥沙利铂前接受加速剂量PS-341输注。 终点是确定PS-341的推荐II期剂量和确定剂量限制性毒性。 将入组15-30例晚期癌症、器官功能良好且既往未暴露于某些类型药物（沙利度胺、细胞增殖活性药物）的患者，参与将涉及3-6个月内的26次输注访视。 研究者继续招募本研究的受试者。 目前尚无数据。